Zymeworks (ZYME) Fundamental Analysis: Revenue, Earnings & Valuation

4.28 / 10

Netural

Fundamental score is 4.3/10, indicating modest health. Strengths include high inventory turnover (103.9) and solid interest coverage (35.1). Weaknesses are modest revenue growth (38.9% YoY) with negative historical returns, and negative Revenue‑MV and Asset‑MV gaps, leading to a neutral stance.

Analysis Checks(8/10)

Revenue-MV

Value-4.55

Score1/3

Weight21.87%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value38.87

Score0/3

Weight-18.95%

1M Return-4.79%

Inventory turnover ratio

Value103.94

Score2/3

Weight-5.02%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value54.24

Score2/3

Weight1.70%

1M Return0.36%

PB-ROE

Value4.22

Score2/3

Weight41.09%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.17

Score3/3

Weight3.85%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-5.11%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value38.87

Score2/3

Weight0.24%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-4.83%

1M Return-1.13%

Asset-MV

Value-0.55

Score2/3

Weight65.14%

1M Return11.12%

Is ZYME undervalued or overvalued?

ZYME scores 4.28/10 on fundamentals and holds a Fair valuation at present. Backed by its -26.72% ROE, -76.56% net margin, -23.58 P/E ratio, 7.12 P/B ratio, and 33.33% earnings growth, these metrics solidify its Netural investment rating.